{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:28:22Z","timestamp":1790447302371,"version":"4.1.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":770,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.bbmt.2012.08.011","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T04:17:25Z","timestamp":1345781845000},"page":"344-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Fifty Years of Melphalan Use in Hematopoietic Stem Cell\u00a0Transplantation"],"prefix":"10.1016","volume":"19","author":[{"given":"Ulas D.","family":"Bayraktar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qaiser","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2012.08.011_bib1","first-page":"6","article-title":"Cytotoxic alpha amino acids and endopeptidase","volume":"31","author":"Bergel","year":"1953","journal-title":"Br Emp Cancer Comp Annu"},{"key":"10.1016\/j.bbmt.2012.08.011_bib2","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1200\/JCO.1988.6.11.1768","article-title":"The systemic administration of intravenous melphalan","volume":"6","author":"Sarosy","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib3","first-page":"1049","article-title":"Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women","volume":"18","author":"Singhal","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib4","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","article-title":"High-dose intravenous melphalan: a review","volume":"13","author":"Samuels","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0005-2736(79)90217-7","article-title":"Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell","volume":"550","author":"Vistica","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bbmt.2012.08.011_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF00273521","article-title":"Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma","volume":"23","author":"Gera","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF00293997","article-title":"Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases","volume":"16","author":"Ardiet","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00256174","article-title":"Pharmacokinetics of high-dose melphalan in children and adults","volume":"16","author":"Gouyette","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF00254244","article-title":"Renal clearance and protein binding of melphalan in patients with cancer","volume":"22","author":"Reece","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0014-2964(78)90253-0","article-title":"Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease","volume":"14","author":"Tattersall","year":"1978","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2012.08.011_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0277-5379(82)90006-2","article-title":"Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma","volume":"18","author":"Bosanquet","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0090-8258(92)90014-A","article-title":"SWOG 8825: melphalan GM-CSF: a phase I study","volume":"44","author":"Poplin","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","article-title":"Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy","volume":"69","author":"Nath","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib14","first-page":"475","article-title":"Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience","volume":"66","author":"Cornwell","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.bbmt.2012.08.011_bib15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2005.1.384","article-title":"Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?","author":"Giralt","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2012.08.011_bib16","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.1997.15.2.660","article-title":"Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma","volume":"15","author":"Moreau","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.1983.1.6.359","article-title":"Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer","volume":"1","author":"Lazarus","year":"1983","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sj.bmt.1705384","article-title":"A\u00a0prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation","volume":"37","author":"Lilleby","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2004.03.001","article-title":"Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study","volume":"10","author":"Phillips","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF00177417","article-title":"Pharmacokinetics of high dose melphalan","volume":"1","author":"Hersh","year":"1983","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bbmt.2012.08.011_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","article-title":"Multiple myeloma treated with high dose intravenous melphalan","volume":"66","author":"Selby","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/bjc.1982.11","article-title":"High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma","volume":"45","author":"Pritchard","year":"1982","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbmt.2012.08.011_bib23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0002-9343(80)90269-7","article-title":"Reversible melphalan-induced lung damage","volume":"68","author":"Westerfield","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2012.08.011_bib24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.bmt.1701217","article-title":"Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells","volume":"21","author":"Olivieri","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib25","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.bjc.6690718","article-title":"High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS\/AML","volume":"81","author":"Harrison","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbmt.2012.08.011_bib27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib28","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbmt.2012.08.011_bib29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2012.08.011_bib30","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","article-title":"High-dose melphalan with autologous bone marrow transplantation for multiple myeloma","volume":"67","author":"Barlogie","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2012.08.011_bib32","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2012.08.011_bib33","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib34","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib35","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib36","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/asheducation-2011.1.191","article-title":"Stem cell transplantation for multiple myeloma: current and future status","volume":"2011","author":"Giralt","year":"2011","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2012.08.011_bib38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib39","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Kumar","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2012.08.011_bib41","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V80.7.1666.1666","article-title":"Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support","volume":"80","author":"Jagannath","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1701763","article-title":"Melphalan 220 mg\/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma","volume":"23","author":"Moreau","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib44","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","article-title":"Melphalan 200 mg\/m(2) versus\u00a0melphalan 100 mg\/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study","volume":"115","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib45","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2012.08.011_bib46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21191","article-title":"Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis","volume":"83","author":"Kumar","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/10428194.2011.606942","article-title":"Feasibility of autologous hematopoietic stem cell transplant in patients aged \u226570 years with multiple myeloma","volume":"53","author":"Bashir","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2012.08.011_bib49","first-page":"947","article-title":"Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study","volume":"2","author":"Tricot","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2012.08.011_bib50","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib51","first-page":"1555","article-title":"The outcome of autologous stem cell transplantation in patients with plasma cell disorders and\u00a0dialysis-dependent renal failure","volume":"91","author":"Raab","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2012.08.011_bib52","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbmt.2009.03.021","article-title":"Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma","volume":"15","author":"Parikh","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib53","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.bbmt.2011.12.014","article-title":"Higher melphalan exposure is associated with improved overall survival for myeloma patients undergoing autologous transplant","volume":"18","author":"Shaw","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib54","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","article-title":"Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial","volume":"117","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib55","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2012.08.011_bib56","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.11644","article-title":"Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma","volume":"93","author":"Lokhorst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2012.08.011_bib58","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2012.08.011_bib59","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib60","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2141.2005.05641.x","article-title":"High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study","volume":"130","author":"Fenk","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib61","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbmt.2008.09.019","article-title":"Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial","volume":"14","author":"Qazilbash","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib62","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12 mg\/kg plus melphalan 140 mg\/m2 versus melphalan 200 mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2012.08.011_bib63","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2\u00a0study of the Intergroupe Francophone du Myelome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"issue":"May 20 suppl","key":"10.1016\/j.bbmt.2012.08.011_bib64","article-title":"Bortezomib\/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005\/01 trial. 2008 ASCO Annual Meeting","volume":"26","author":"Harousseau","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib65","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/cncr.26517","article-title":"A\u00a0randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2012.08.011_bib66","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib67","unstructured":"Durie BG. Allogeneic bone marrow transplants for multiple myeloma: an IBMTR analysis (meeting abstract). 1995 ASCO Annual Meeting: abstract\u00a01358."},{"key":"10.1016\/j.bbmt.2012.08.011_bib68","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib69","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","article-title":"Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning","volume":"109","author":"Crawley","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib70","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib71","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kr\u00f6ger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib72","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2008-07-170746","article-title":"Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting","volume":"113","author":"Rotta","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib73","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2008-07-167379","article-title":"Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo","volume":"113","author":"Bruno","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0301-472X(02)01010-X","article-title":"Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning","volume":"31","author":"Lee","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib75","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib76","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A\u00a0prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib77","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A\u00a0comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2012.08.011_bib78","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor analysis of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib79","doi-asserted-by":"crossref","unstructured":"Gahrton G, Bjorkstrand B, Iacobelli S, et\u00a0al. Tandem autologous (ASCT)\/allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): long term follow up of a prospective controlled trial by the EBMT. 52st ASH Annual Meeting and Exposition. 2009: abstract\u00a052.","DOI":"10.1182\/blood.V114.22.52.52"},{"key":"10.1016\/j.bbmt.2012.08.011_bib80","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up","volume":"29","author":"Bj\u00f6rkstrand","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib81","doi-asserted-by":"crossref","unstructured":"Krishnan A, Pasquini MC, Ewell M, et\u00a0al. Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA matched sibling non- myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. 53rd ASH Annual Meeting and Exposition. December 2010: abstract\u00a041.","DOI":"10.1182\/blood.V116.21.41.41"},{"key":"10.1016\/j.bbmt.2012.08.011_bib82","doi-asserted-by":"crossref","unstructured":"Knop S, Liebisch P, Hebart H, et\u00a0al. Allogeneic stem cell transplant\u00a0versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma: an interim analysis of the German DSMM V trial. 52nd ASH Annual Meeting and Exposition. 2009: abstract\u00a051.","DOI":"10.1182\/blood.V114.22.51.51"},{"key":"10.1016\/j.bbmt.2012.08.011_bib83","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1182\/blood-2008-07-168823","article-title":"Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma","volume":"112","author":"Moreau","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib84","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib85","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib86","doi-asserted-by":"crossref","unstructured":"Knop S, Liebisch P, Hebart H, et\u00a0al. Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma \u2013 an interim analysis of the German DSMM V Trial. 52st ASH Annual Meeting and Exposition. 2009: abstract\u00a051.","DOI":"10.1182\/blood.V114.22.51.51"},{"key":"10.1016\/j.bbmt.2012.08.011_bib87","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2012.08.011_bib88","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib89","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone\u00a0+\/\u2212 thalidomide for systemic light-chain amyloidosis: results of a phase II trial","volume":"139","author":"Cohen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib90","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2010-04-279901","article-title":"I\u00a0don't know how to treat amyloidosis","volume":"116","author":"Gertz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib91","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.2008.07327.x","article-title":"Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone","volume":"143","author":"Lebovic","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib92","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood-2009-11-253237","article-title":"Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement","volume":"116","author":"Dietrich","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib93","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2007.06936.x","article-title":"Perspectives in treatment of AL amyloidosis","volume":"140","author":"Wechalekar","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib94","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","article-title":"Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival","volume":"19","author":"Dispenzieri","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib95","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","article-title":"Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study","volume":"103","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib96","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2012.08.011_bib97","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJMc072918","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"358","author":"Kumar","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2012.08.011_bib98","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.bmt.1705746","article-title":"Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis","volume":"40","author":"Sanchorawala","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib99","first-page":"21","article-title":"Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission","volume":"3","author":"Helenglass","year":"1988","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib100","first-page":"105","article-title":"Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission","volume":"3","author":"Michel","year":"1988","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib101","first-page":"445","article-title":"High-dose melphalan with or without marrow transplantation: a study of dose-effect in patients with refractory and\/or relapsed acute leukemias","volume":"70","author":"Maraninchi","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.bbmt.2012.08.011_bib102","article-title":"Preliminary results of fludarabine\/melphalan or 2CDA\/melphalan (2CDA\/M) as preparative regimens for allogeneic progenitor cell transplantation (allo-PCT) in poor candidates for conventional myeloablative conditioning","volume":"90","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib103","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib104","first-page":"3101","article-title":"Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results","volume":"28","author":"Terenzi","year":"1996","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2012.08.011_bib105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","article-title":"Cellular and clinical pharmacology of fludarabine","volume":"41","author":"Gandhi","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bbmt.2012.08.011_bib106","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2006.11.024","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan","volume":"13","author":"Oran","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib107","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1200\/JCO.2005.15.602","article-title":"Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"van Besien","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib108","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","article-title":"Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes","volume":"15","author":"van Besien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib110","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","article-title":"Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia","volume":"99","author":"Devine","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib111","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib112","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bbmt.2006.06.014","article-title":"Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis","volume":"12","author":"Snyder","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib113","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2009.12.004","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation","volume":"16","author":"Ciurea","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib114","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nrd2055","article-title":"Discovery and development of clofarabine: a nucleoside analogue for treating cancer","volume":"5","author":"Bonate","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bbmt.2012.08.011_bib115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/0091270010372519","article-title":"Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation","volume":"51","author":"Long-Boyle","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib116","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbmt.2011.10.041","article-title":"Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation","volume":"18","author":"van Besien","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib117","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2012.08.011_bib118","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/0277-5379(86)90070-2","article-title":"Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt\u2019s lymphoma (30 courses on 28 patients: a 5-year experience)","volume":"22","author":"Philip","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib119","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/BF00256170","article-title":"Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma","volume":"16","author":"Anderson","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib120","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib121","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00273421","article-title":"Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies","volume":"22","author":"Gaspard","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib122","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib123","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ijrobp.2009.08.024","article-title":"Total body irradiation compared with BEAM: long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma","volume":"78","author":"Liu","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bbmt.2012.08.011_bib124","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2010.07.016","article-title":"BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2012.08.011_bib125","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1023\/A:1008396525292","article-title":"High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease","volume":"11","author":"Argiris","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib126","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.2000.02098.x","article-title":"Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial","volume":"109","author":"Deconinck","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib127","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib128","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00277-004-1003-3","article-title":"Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-\/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR)","volume":"84","author":"Nachbaur","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib129","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2012.08.011_bib130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/bmt.2009.318","article-title":"Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study","volume":"45","author":"Musso","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib131","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib132","first-page":"323","article-title":"Busulfan and melphalan prior to autologous bone marrow transplantation","volume":"12","author":"Srivastava","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib133","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bbmt.2010.07.016","article-title":"Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies","volume":"17","author":"Kebriaei","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib134","doi-asserted-by":"crossref","unstructured":"Nieto Y, Anderlini P, Popat U, et\u00a0al. Gemcitabine, busulfan and melphalan (GemBuMel) is a new high-dose chemotherapy (HDC) regimen with high activity in refractory Hodgkin's lymphoma (HL) patients receiving an autologous stem-cell transplant (ASCT): a contemporaneous comparison with BEAM and busulfan\/melphalan (BuMel). 53rd ASH Annual Meeting and Exposition. 2010:abstract\u00a0690.","DOI":"10.1182\/blood.V116.21.690.690"},{"key":"10.1016\/j.bbmt.2012.08.011_bib135","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a010369","article-title":"Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma","volume":"10","author":"Przepiorka","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib136","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-2141.2000.01879.x","article-title":"Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity","volume":"108","author":"Cull","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib137","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","article-title":"BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients","volume":"103","author":"Faulkner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib138","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.bmt.1702580","article-title":"Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease","volume":"26","author":"Anderlini","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib139","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","article-title":"Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies","volume":"20","author":"Branson","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib140","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","article-title":"Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study","volume":"107","author":"Delgado","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib141","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","article-title":"Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience","volume":"93","author":"Anderlini","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2012.08.011_bib142","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.bmt.1700964","article-title":"Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan)","volume":"20","author":"Deconinck","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib143","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.1994.12.12.2580","article-title":"Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia","volume":"12","author":"Sebban","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib144","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1200\/JCO.1988.6.10.1548","article-title":"A\u00a0comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission","volume":"6","author":"Zander","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib145","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/leu.2009.102","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study","volume":"23","author":"Cho","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2012.08.011_bib146","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbmt.2005.01.012","article-title":"Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma","volume":"11","author":"Yuji","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib147","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2010.192","article-title":"Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis","volume":"46","author":"Cutler","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib148","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bbmt.2010.09.005","article-title":"Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients","volume":"17","author":"Waki","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib149","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1083-8791(03)00263-5","article-title":"Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen","volume":"9","author":"Lacerda","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bcmd.2007.07.001","article-title":"Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3\/CD19 depletion and reduced intensity conditioning: an update","volume":"40","author":"Bethge","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.bbmt.2012.08.011_bib151","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bbmt.2010.11.020","article-title":"Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation","volume":"17","author":"Ciurea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib152","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/bmt.2009.189","article-title":"Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT","volume":"45","author":"Ciurea","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib153","doi-asserted-by":"crossref","unstructured":"Ciurea SO, Saliba RM, Bayraktar UD, et\u00a0al. Improved early outcomes with T-cell replete (TCR) compared with T-cell depleted (TCD) haploidentical stem cell transplantation (HaploSCT). 53rd ASH Annual Meeting and Exposition. 2011: abstract\u00a0320.","DOI":"10.1182\/blood.V118.21.320.320"},{"key":"10.1016\/j.bbmt.2012.08.011_bib154","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib155","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib156","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-0609.2004.00266.x","article-title":"Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies","volume":"73","author":"Malladi","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib157","doi-asserted-by":"crossref","first-page":"9387","DOI":"10.1200\/JCO.2005.02.0057","article-title":"Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia","volume":"23","author":"Tauro","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib158","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/sj.bmt.1705801","article-title":"Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome","volume":"40","author":"Nakamura","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib159","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2006.10.005","article-title":"Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies","volume":"13","author":"Small","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib160","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.leu.2405014","article-title":"Phase I\/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome","volume":"22","author":"de Lima","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2012.08.011_bib161","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2007-08-104745","article-title":"Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies","volume":"112","author":"Marks","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib162","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2011.07.017","article-title":"A\u00a0phase i study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation","volume":"18","author":"Kirschbaum","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib163","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2012.08.011_bib164","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib165","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2012.08.011_bib166","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2012.08.011_bib167","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2141.2007.06759.x","article-title":"Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes","volume":"139","author":"Peggs","year":"2007","journal-title":"Br J Haematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879112003333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879112003333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:46:19Z","timestamp":1761057979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879112003333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":167,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1083879112003333"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2012.08.011","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fifty Years of Melphalan Use in Hematopoietic Stem Cell\u00a0Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2012.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}